Literature DB >> 20332404

Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis.

Dirk Bassler1, Matthias Briel, Victor M Montori, Melanie Lane, Paul Glasziou, Qi Zhou, Diane Heels-Ansdell, Stephen D Walter, Gordon H Guyatt, David N Flynn, Mohamed B Elamin, Mohammad Hassan Murad, Nisrin O Abu Elnour, Julianna F Lampropulos, Amit Sood, Rebecca J Mullan, Patricia J Erwin, Clare R Bankhead, Rafael Perera, Carolina Ruiz Culebro, John J You, Sohail M Mulla, Jagdeep Kaur, Kara A Nerenberg, Holger Schünemann, Deborah J Cook, Kristina Lutz, Christine M Ribic, Noah Vale, German Malaga, Elie A Akl, Ignacio Ferreira-Gonzalez, Pablo Alonso-Coello, Gerard Urrutia, Regina Kunz, Heiner C Bucher, Alain J Nordmann, Heike Raatz, Suzana Alves da Silva, Fabio Tuche, Brigitte Strahm, Benjamin Djulbegovic, Neill K J Adhikari, Edward J Mills, Femida Gwadry-Sridhar, Haresh Kirpalani, Heloisa P Soares, Paul J Karanicolas, Karen E A Burns, Per Olav Vandvik, Fernando Coto-Yglesias, Pedro Paulo M Chrispim, Tim Ramsay.   

Abstract

CONTEXT: Theory and simulation suggest that randomized controlled trials (RCTs) stopped early for benefit (truncated RCTs) systematically overestimate treatment effects for the outcome that precipitated early stopping.
OBJECTIVE: To compare the treatment effect from truncated RCTs with that from meta-analyses of RCTs addressing the same question but not stopped early (nontruncated RCTs) and to explore factors associated with overestimates of effect. DATA SOURCES: Search of MEDLINE, EMBASE, Current Contents, and full-text journal content databases to identify truncated RCTs up to January 2007; search of MEDLINE, Cochrane Database of Systematic Reviews, and Database of Abstracts of Reviews of Effects to identify systematic reviews from which individual RCTs were extracted up to January 2008. STUDY SELECTION: Selected studies were RCTs reported as having stopped early for benefit and matching nontruncated RCTs from systematic reviews. Independent reviewers with medical content expertise, working blinded to trial results, judged the eligibility of the nontruncated RCTs based on their similarity to the truncated RCTs. DATA EXTRACTION: Reviewers with methodological expertise conducted data extraction independently.
RESULTS: The analysis included 91 truncated RCTs asking 63 different questions and 424 matching nontruncated RCTs. The pooled ratio of relative risks in truncated RCTs vs matching nontruncated RCTs was 0.71 (95% confidence interval, 0.65-0.77). This difference was independent of the presence of a statistical stopping rule and the methodological quality of the studies as assessed by allocation concealment and blinding. Large differences in treatment effect size between truncated and nontruncated RCTs (ratio of relative risks <0.75) occurred with truncated RCTs having fewer than 500 events. In 39 of the 63 questions (62%), the pooled effects of the nontruncated RCTs failed to demonstrate significant benefit.
CONCLUSIONS: Truncated RCTs were associated with greater effect sizes than RCTs not stopped early. This difference was independent of the presence of statistical stopping rules and was greatest in smaller studies.

Mesh:

Year:  2010        PMID: 20332404     DOI: 10.1001/jama.2010.310

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  134 in total

1.  VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Shannon M Bates; Ian A Greer; Saskia Middeldorp; David L Veenstra; Anne-Marie Prabulos; Per Olav Vandvik
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Statins in combinations: from ARBITER-6 HALTS to ACCORD--what works?

Authors:  Michael Clearfield
Journal:  Curr Atheroscler Rep       Date:  2011-02       Impact factor: 5.113

Review 3.  Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: analysis of individual patients' data from four randomized trials and trial-level meta-analysis of the updated literature.

Authors:  G Umberto Meduri; Lisa Bridges; Mei-Chiung Shih; Paul E Marik; Reed A C Siemieniuk; Mehmet Kocak
Journal:  Intensive Care Med       Date:  2015-10-27       Impact factor: 17.440

4.  The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design.

Authors:  Munyaradzi Dimairo; Philip Pallmann; James Wason; Susan Todd; Thomas Jaki; Steven A Julious; Adrian P Mander; Christopher J Weir; Franz Koenig; Marc K Walton; Jon P Nicholl; Elizabeth Coates; Katie Biggs; Toshimitsu Hamasaki; Michael A Proschan; John A Scott; Yuki Ando; Daniel Hind; Douglas G Altman
Journal:  BMJ       Date:  2020-06-17

Review 5.  Hyperbaric oxygen for carbon monoxide poisoning.

Authors:  Nick A Buckley; David N Juurlink; Geoff Isbister; Michael H Bennett; Eric J Lavonas
Journal:  Cochrane Database Syst Rev       Date:  2011-04-13

6.  Monitoring in clinical trials: benefit or bias?

Authors:  Cecilia Nardini
Journal:  Theor Med Bioeth       Date:  2013-08

Review 7.  [Randomized controlled trials terminated prematurely: beneficial therapy effects].

Authors:  L A Kluth; M Rink; S A Ahyai; M Fisch; S F Shariat; P Dahm
Journal:  Urologe A       Date:  2013-08       Impact factor: 0.639

8.  Quantifying over-estimation in early stopped clinical trials and the "freezing effect" on subsequent research.

Authors:  Hao Wang; Gary L Rosner; Steven N Goodman
Journal:  Clin Trials       Date:  2016-06-07       Impact factor: 2.486

9.  Adjuvant trastuzumab for breast cancer: uncertainties in clinical and economic evidence following early stopping of the HERA trial.

Authors:  Tallal Younis; Chris Skedgel
Journal:  Pharmacoeconomics       Date:  2011-05       Impact factor: 4.981

Review 10.  Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learned.

Authors:  James C Yao; Diane Reidy Lagunes; Matthew H Kulke
Journal:  Oncologist       Date:  2013-04-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.